Welcome to our dedicated page for Insulet SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insulet Corporation filings document the financial, regulatory, governance, and operating disclosures of a medical device company built around the Omnipod tubeless insulin delivery platform. Current reports record quarterly and annual results, Omnipod revenue categories, U.S. and international performance, drug delivery revenue, and related financial-condition disclosures.
Insulet’s SEC filings also cover Regulation FD updates on product-quality and medical device correction matters, material supply agreements, stock repurchase authorizations, executive severance arrangements, auditor changes, and proxy governance. Its definitive proxy materials describe board oversight, executive compensation, leadership structure, and other shareholder-voting matters tied to the company’s public-company governance.
INSULET CORP director Timothy C. Stonesifer bought shares of the company in the open market. On June 3, he purchased 2,790 shares of Insulet common stock at $143.51 per share. After this transaction, his direct holdings increased to 9,041 common shares.
INSULET CORP director Luciana Borio sold 418 shares of Common Stock in an open-market transaction on June 3, 2026, at an average price of $143.27 per share. After this sale, she directly owns 4,329 company shares, indicating she retains a meaningful ongoing equity stake.
INSULET CORP director Elizabeth H. Weatherman reported an open-market purchase of Common Stock. She bought 3,450 shares at a weighted average price of $144.20 per share, increasing her direct holdings to 10,352 shares after the transaction.
The shares were acquired in multiple trades: 1,607 shares at prices ranging from $143.21 to $144.13 with a weighted average of $143.65, and 1,843 shares at prices ranging from $144.22 to $145 with a weighted average of $144.69.
Insulet Corporation announced a voluntary Medical Device Correction covering specific lots of Omnipod 5, Omnipod DASH, and Omnipod Eros Pods due to a manufacturing issue that can cause insulin under-delivery. The issue stems from cannula tears that may lead to insulin leaking outside the Pod and high blood glucose.
Approximately 7 million Pods are in scope, about 60% of which have already been consumed or expired, and the affected Pods represent roughly 8.5% of 2025 global Omnipod Pod production. Globally, there have been 24 reports of serious adverse events, including hospitalization and diabetic ketoacidosis, but no deaths.
The company has identified the cause, implemented corrective and enhanced quality controls, and is offering free replacement Pods to affected customers. Insulet currently expects up to $50 million of related costs in 2026, to be excluded from adjusted results, and is maintaining its previously issued 2026 guidance and long-term growth outlook.
WEATHERMAN ELIZABETH H reported acquisition or exercise transactions in this Form 4 filing.
Insulet Corp director Elizabeth H. Weatherman received an annual equity award of 1,660 restricted stock units (RSUs). The award is priced at $0.00 per share, indicating it is a stock-based compensation grant rather than a market purchase. These RSUs will settle into common shares on a one-for-one basis and vest in full on April 30, 2027. After this grant, she holds a total of 6,902 shares of Insulet common stock directly.
STONESIFER TIMOTHY C. reported acquisition or exercise transactions in this Form 4 filing.
INSULET CORP director Timothy C. Stonesifer received an annual equity award of 1,660 restricted stock units. The RSUs will settle one-for-one in common stock and vest in full on April 30, 2027. Following this grant, he directly holds 6,251 shares, reflecting routine, compensation-related equity rather than an open-market purchase.
INSULET CORP director Timothy J. Scannell received an annual equity award in the form of restricted stock units. The grant covers 1,660 shares of common stock, awarded at no cash cost and recorded as an acquisition of common stock.
The RSUs will be settled in shares of common stock on a one-for-one basis and vest in full on April 30, 2027. After this award, Scannell directly holds 33,024 shares of Insulet common stock, showing this is a routine, compensation-related equity grant rather than an open-market purchase or sale.
MINOGUE MICHAEL R reported acquisition or exercise transactions in this Form 4 filing.
INSULET CORP director Michael R. Minogue reported an equity grant and updated share holdings. He received an annual equity award of 1,660 restricted stock units (RSUs), which will be settled one-for-one in common shares and vest in full on April 30, 2027. Following the grant, he holds 2,438 common shares directly and 17,483 common shares indirectly through a trust.
Huffines Robert Luther reported acquisition or exercise transactions in this Form 4 filing.
Insulet Corp director Robert Luther Huffines received an annual equity award of 1,660 shares of common stock in the form of restricted stock units at no cash cost. These RSUs vest in full on April 30, 2027 and will be settled one-for-one in shares after his board service ends, according to his deferral election. Following this grant, he beneficially owns 2,298 common shares directly.